Andreas Neubauer
Overview
Explore the profile of Andreas Neubauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
5405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esteve J, Nagler A, Labopin M, Versluis J, Sanz J, Gedde-Dahl T, et al.
Am J Hematol
. 2025 Mar;
PMID: 40062532
Patients (pts) with myelodysplasia-related AML (MR-AML) are now genetically recategorized, with three different groups in the International Consensus Classification: AML with mutated TP53 (TP53-AML), with myelodysplasia-related gene mutations (MR-GM AML),...
2.
Stasik S, Eckardt J, Rollig C, Baldus C, Platzbecker U, Serve H, et al.
Br J Haematol
. 2025 Mar;
PMID: 40041934
IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the...
3.
Duque-Afonso J, Finke J, Ngoya M, Galimard J, Schetelig J, Eder M, et al.
Bone Marrow Transplant
. 2024 Dec;
60(3):373-379.
PMID: 39702670
The treatment of relapsed/refractory acute myeloid leukemia (AML) is associated with a dismal prognosis. The allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed as salvage therapy. Reduced intensity conditioning protocols...
4.
Schmalter A, Labopin M, Versluis J, Gallego Hernanz M, Eder M, Borne P, et al.
Am J Hematol
. 2024 Nov;
100(1):85-92.
PMID: 39558209
Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease-defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification....
5.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
6.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, et al.
Eur J Haematol
. 2024 Oct;
114(2):231-237.
PMID: 39400388
In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also...
7.
Rollig C, Steffen B, Schliemann C, Mikesch J, Alakel N, Herbst R, et al.
J Clin Oncol
. 2024 Sep;
43(1):65-74.
PMID: 39284116
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60...
8.
Acker F, Chromik J, Tiedjen E, Wolf S, Vischedyk J, Makowka P, et al.
Eur J Haematol
. 2024 Jul;
113(5):623-630.
PMID: 39023132
Background: First-line treatment in patients with acute myeloid leukemia (AML) unfit for intensive therapy is the combination of a hypomethylating agent (HMA) with venetoclax (VEN). However, retrospective data confirming the...
9.
Tarawneh T, Mack E, Faoro C, Neubauer A, Middeke M, Kirschbaum A, et al.
BMC Pulm Med
. 2024 Jul;
24(1):320.
PMID: 38965500
Background: The COVID-19 pandemic has had negative drawbacks on the healthcare system worldwide and on individuals other than those directly affected by the virus. Delays in cancer therapy and diagnosis...
10.
Fischbach W, Neubauer A, Reinartz G
Inn Med (Heidelb)
. 2024 Jun;
65(7):690-700.
PMID: 38833003
Mucosa-associated lymphomas of the gastrointestinal tract are a heterogeneous group differing in pathogenesis, localization and therapeutic options. For all of them, differentiated treatment requires an exact determination of lymphoma stage....